Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately

This article was originally published in The Pink Sheet Daily

Executive Summary

The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.

You may also be interested in...

A Challenging Q3 For Novartis, But Diovan Generic Delay Offers A Reprieve

The unexpected delay of U.S. generic competition to Diovan helped pad some of the impact felt by Novartis from the loss of exclusivity on the blockbuster hypertension drug. Still, the impact of generics weighed on Novartis’ third quarter sales, and the delay is only a temporary reprieve of the inevitable sales erosion.

AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label

Europe's CHMP takes divergent stance to FDA on dapagliflozin, clearing it for treating diabetes if AstraZeneca and Bristol-Myers Squibb conduct a post-marketing study. The committee also cleared ruxolitinib and ferumoxytol, but rejected Folotyn, for EU marketing.

Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing

Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts